Your shopping cart is currently empty

VR17-04, a metabolite of Enisamium, inhibits the incorporation of GTP and UTP during RNA synthesis. Its mechanism of action was elucidated through docking and molecular dynamics simulations. These findings suggest that VR17-04 could serve as a potential antiviral strategy for managing COVID-19.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | VR17-04, a metabolite of Enisamium, inhibits the incorporation of GTP and UTP during RNA synthesis. Its mechanism of action was elucidated through docking and molecular dynamics simulations. These findings suggest that VR17-04 could serve as a potential antiviral strategy for managing COVID-19. |
| Synonyms | VR1704, VR17 04 |
| Molecular Weight | 243.28 |
| Formula | C14H15N2O2 |
| Cas No. | 2417925-64-3 |
| Smiles | O=C(NCC=1C=CC=CC1)C2=CC=[N+](C=C2O)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.